Preclinical Comparison of the Amyloid-β Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis

Molecular Imaging and Biology

Volumn 17, Issue 5, 2015, Pages 688-696

  Waldron, Ann Marie ^a   Verhaeghe, Jeroen ^a   wyffels, Leonie ^a,b   Schmidt, Mark ^c   Langlois, Xavier ^c   Van Der Linden, Annemie ^a   Stroobants, Sigrid ^b   Staelens, Steven ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Alzheimer s; Animal models; Small animal imaging; 11C PiB; 18F FBB

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETAPIR F 18; PITTSBURGH COMPOUND B; RADIOLIGAND; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; STILBENE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; EX VIVO STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENILE PLAQUE; THALAMUS; VASCULAR AMYLOIDOSIS; ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DISEASE MODEL; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ANIMALS; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STILBENES; THIAZOLES;

EID: 84941997343     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0833-9     Document Type: Article

References (44)

1. Selkoe DJ (1991) The molecular pathology of Alzheimer’s. Neuron 6:487–498
2. Nordberg A (2011) Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3:34
3. Reiman EM, Jagust WJ (2012) Brain imaging in the study of Alzheimer’s disease. Neuroimage 61:505–516
4. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55:306–319
5. Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452
6. Manook A, Yousefi BH, Willuweit A et al (2012) Small-animal PET imaging of amyloid-beta plaques with [11C] PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer’s disease. PLoS One 7:e31310
7. Maeda J, Ji B, Irie T et al (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci 27:10957–10968
8. von Reutern B, Grünecker B, Yousefi BH, et al. (2013) Voxel-based analysis of amyloid-burden measured with [11C]PiB PET in a double transgenic mouse model of Alzheimer’s disease. Mol Imaging Biol
9. Nelissen N, Van Laere K, Thurfjell L et al (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50:1251–1259
10. Rowe CC, Ellis KA, Rimajova M et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275–1283
11. Wong DF, Moghekar AR, Rigamonti D et al (2013) An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 15:230–237
12. Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–135
13. Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11:669–678
14. Wong DF, Rosenberg PB, Zhou Y et al (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51:913–920
15. Cselenyi Z, Jonhagen ME, Forsberg A et al (2012) Clinical validation of 18F-AZD4694, an amyloid-b -specific PET radioligand. J Nucl Med 53:415–424
16. Ni R, Gillberg PG, Bergfors A et al (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136:2217–2227
17. Snellman A, Lopez-Picon FR, Rokka J et al (2013) Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med 54:1434–1441
18. Poisnel GG, Dhilly MM, Moustié OO et al (2012) PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging 33:2561–2571
19. Rominger A, Brendel M, Burgold S et al (2013) Longitudinal assessment of cerebral beta-Amyloid deposition in mice overexpressing Swedish mutant beta-amyloid precursor protein using 18F-Florbetaben PET. J Nucl Med 54:1127–1134
20. Kepe V, Moghbel MC, Långström B et al (2013) Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis 36:613–631
21. Radde R, Bolmont T, Kaeser SA et al (2006) Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940–946
22. McGowan E, Pickford F, Kim J et al (2005) Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191–199
23. Levites Y, Smithson LA, Price RW et al (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models. FASEB J 20:2576–2578
24. Hudson HM, Larkin RS (1994) Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 13:601–609
25. Defrise M, Kinahan PE, Townsend DW et al (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16:145–158
26. Watson CC (2000) New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 47:1587–1594
27. Mirrione MM, Schiffer WK, Fowler JS et al (2007) A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 38:34–42
28. Franklin KB, Paxinos G (1997) Mouse brain in stereotaxic coordinates
29. Rojas S, Herance JR, Gispert JD et al (2013) In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging 34:1790–1798
30. Landau SM, Breault C, Joshi AD et al (2013) Amyloid-b imaging with Pittsburgh compound B and Florbetapir: comparing radiotracers and quantification methods. J Nucl Med 54:70–77
31. Villemagne VL, Mulligan R, Pejoska S et al (2012) Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:983–989
32. Rowe CC, Pejoska S, Mulligan RS et al (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for b-amyloid imaging in aging and dementia. J Nucl Med 54:880–886
33. Pike VW (2009) PET radiotracers: crossing the blood–brain barrier and surviving metabolism. Trends Pharmacol Sci 30:431–440
34. Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 25:1528–1547
35. Fodero-Tavoletti MT, Rowe CC, McLean CA et al (2009) Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med 50:198–204
36. Snellman A, Rokka J, Lopez-Picon FR et al (2012) Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:1784–1795
37. Patt M, Schildan A, Barthel H et al (2010) Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanal Nucl Chem 284:557–562
38. Brendel M, Delker A, Rötzer C et al (2014) Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET. Neuroimage 84:843–853
39. Cole GB, Keum G, Liu J et al (2010) Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Natl Acad Sci U S A 107:6222–6227
40. Lockhart A, Lamb JR, Osredkar T et al (2007) PIB is a non-specific imaging marker of amyloid-beta (A) peptide-related cerebral amyloidosis. Brain 130:2607–2615
41. Kara F, van Dongen ES, Schliebs R et al (2012) Monitoring blood flow alterations in the Tg2576 mouse model of Alzheimer’s disease by in vivo magnetic resonance angiography at 17.6T. Neuroimage 60:958–966
42. Klunk WE, Lopresti BJ, Ikonomovic MD et al (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 25:10598–10606
43. Toyama H, Ye D, Ichise M et al (2005) PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 32:593–600
44. Maier FC, Wehrl HF, Schmid AM et al (2014) Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med 20:1485–1492